

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (withdrawn)

2. (canceled)

3.-6. (withdrawn)

7. (canceled)

8. (canceled)

9.-11. (withdrawn)

12. (canceled)

13. (currently amended) A method for stimulating an immune response in a patient, comprising administering to the patient a composition of claim ~~12~~20.

21 14. (currently amended) A method for the treatment of a lung cancer in a patient, comprising administering to the patient a composition of claim ~~12~~20.

15.-19. (withdrawn)

20. (new) An immunogenic composition comprising an adjuvant, wherein said adjuvant induces a predominantly Th1-type response, and a polypeptide selected from the group consisting of:

(i) a polypeptide comprising the amino acid sequence provided in SEQ ID NO:176, or a portion thereof;

(ii) a polypeptide comprising an amino acid sequence having at least 90% identity to the sequence provided in SEQ ID NO:176, or a portion thereof;

wherein said polypeptide contains an amino acid sequence that is capable of stimulating T cells that are specific for an amino acid sequence present in the polypeptide set forth in SEQ ID NO:176.

21. (new) The immunogenic composition according to claim 20, wherein the adjuvant comprises an adjuvant selected from the group consisting of a monophosphoryl lipid A, an aluminum salt, QS21, Montanide ISA 720, SAF, ISCOMS, MF-59, SBAS-2, SBAS-4, Detox, RC-529, and an aminoalkyl glucosaminide 4-phosphate.

22. (new) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 37-55 of the amino acid sequence provided in SEQ ID NO:176.

23. (new) The immunogenic composition according to claim 20, wherein said polypeptide comprises amino acid positions 41-51 of the amino acid sequence provided in SEQ ID NO:176.